Comparing the trends of cancer burden attributed to high BMI in China and globally from 1990 to 2021, with multi-model prediction to 2036
Bibliographic Data
Introduction: High body mass index (BMI) has been identified as a significant contributor to cancers. However, details regarding the evolution of the cancer burden attributable to high BMI in China have not been available. With the epidemic of high BMI among Chinese recent years, it's essential to evaluate the disease burden of cancer associated with high BMI to guide disease interventions and enhance public health. This study aimed to evaluate the burden of high BMI-attributed cancer in China from 1990 to 2021 and compare it with global trends. Methods: The temporal trends of high BMI-attributed cancer were assessed using annual percentage change (APC) and overall percentage change. Decomposition and age-period-cohort analyses were conducted to identify influential factors, while future trends were projected with the Bayesian age-period-cohort (BAPC), auto-regressive moving average model (ARIMA), and exponential smoothing model (ETS). Results: in 2021, remaining below the global average. While the APC of ASMR and ASDR constantly increased in China, global trends exhibited minimal change. Colorectal and liver cancers were the most prevalent types of high BMI-attributed cancer. In China, the period and cohort effects on high BMI-attributed cancer increased more significantly, with the age effect showing an exponential rise. Aging accounted for 43.92% of high BMI-attributed cancer related deaths and 40.03% of disability-adjusted life-years (DALYs) in China. Over the next 15 years, the burden of high BMI-attributed cancer in China would show a more significant upward trend compared with global trends. Conclusions: Although China's current high BMI-attributed cancer burden remains below the global average, it is increasing at a substantial rate and is expected to continue increasing rapidly. Targeted prevention strategies tailored to age and the latest high BMI-attributed cancer spectrum are urgently needed to mitigate this growing public health concern in China
Body mass index · Cancer · Cohort · Cancer Risks and Factors · Demography · Medicine · Metabolism, Diabetes, and Cancer · Multiple and Secondary Primary Cancers · Gerontology · Internal Medicine
A research agenda for aging in China in the 21st century
Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021
Body-mass index and obesity in urban and rural China
Global mortality, disability, and the contribution of risk factors
Permutation tests for joinpoint regression with applications to cancer rates
‘Mendelian randomization’
Comparative quantification of health risks
A Web Tool for Age–Period–Cohort Analysis of Cancer Incidence and Mortality Rates
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (Dalys), and healthy life expectancy (Hale) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021
Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016
The global burden of disease attributable to high body mass index in 195 countries and territories, 1990–2017
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050
Global Cancer Statistics 2020
Impact of sustained health policy and population-level interventions on reducing the prevalence of obesity in the Caribbean region
Projection of the prevalence of tracheal, bronchus, and lung cancer incidence using cigarette smoking prevalence in Iran from 1990 to 2018
Trends of older gastric cancer incidence, mortality, and survival in the highest gastric cancer risk area in China
Decline of childhood overweight and obesity in Italy from 2008 to 2016
| Citations per year | 1 |
|---|---|
| Citation span | 2025 - 2025 (1) |
| Highly cited | No |